In conclusion, we identified that GALT3 could be recognised by HLA-A2-restricted and tumour-reactive CTLs and that two GALT3 peptides were capable of inducing brain tumour-reactive CTLs from HLA-A2+ patients with brain tumours. The gene discussed is B3GALNT1; the disease is neoplasm.